Celsion (NASDAQ: CLSN) recently received a number of ratings updates from brokerages and research firms:

  • 1/19/2016 – Celsion had its price target raised by analysts at Maxim Group from $9.00 to $12.00. They now have a “buy” rating on the stock. They wrote, “We reviewed our assumptions around the ThermoDox phase III OPTIMA Study in primary liver cancer (hepatocellular carcinoma [HCC]), and, while we are excited about the prospects of the trial timeline (complete enrollment in 2017E, data in 2018E), we see a data trough in 2016. While we are awaiting data, Celsion is beginning to focus on its immune-oncology programs, particularly GEN-1 (DNA-based IL-12 in ovarian cancer). While we do see catalysts (the IL-12 program), we believe the key event remains the OPTIMA Study.””
  • 1/19/2016 – Celsion was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
  • 1/18/2016 – Celsion was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.50 price target on the stock. According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
  • 1/12/2016 – Celsion was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
  • 12/16/2015 – Celsion had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $12.00 price target on the stock. They wrote, “Celsion announced that the China Food and Drug Administration (CFDA) approved the company’s application to conduct the pivotal phase III OPTIMA study at sites in China.””

Shares of Celsion Co. (NASDAQ:CLSN) traded down 3.214% during mid-day trading on Tuesday, reaching $1.355. The company’s stock had a trading volume of 23,170 shares. The firm’s market cap is $31.49 million. The firm’s 50 day moving average is $1.74 and its 200 day moving average is $1.96. Celsion Co. has a one year low of $1.16 and a one year high of $3.57.

Celsion (NASDAQ:CLSN) last announced its earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.06. On average, equities analysts anticipate that Celsion Co. will post ($1.03) earnings per share for the current fiscal year.

In other news, major shareholder Egwu, Inc. Fka Egen, Inc. sold 20,000 shares of Celsion stock in a transaction that occurred on Monday, November 30th. The shares were sold at an average price of $2.15, for a total transaction of $43,000.00. Following the completion of the sale, the insider now owns 2,442,423 shares of the company’s stock, valued at $5,251,209.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Celsion Corporation (NASDAQ:CLSN) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

12 Month Chart for NASDAQ:CLSN

Receive News & Ratings for Celsion Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Co and related companies with MarketBeat.com's FREE daily email newsletter.